A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through high-throughput small molecule screens we identified the antibiotic Novobiocin (NVB) as a specific POLθ inhibitor that selectively kills HR-deficient tumor cells
Journal
Nature CancerAuthors
Funding
Mesoscale and Nanoscale Technologies Integrated by Structures for DNA Repair Complexes (MANTIS-DRC)Molecular Pathogenesis of Fanconi AnemiaMolecular Pathogenesis of Fanconi AnemiaCore B: Biostatistics and Computational Biology CoreCore 1: Expression and Molecular Biology (EMB)Pathophysiology and Treatment of Fanconi AnemiaInvestigating DNA repair vulnerabilities in oncometabolite producing cancers